|
|
|
|
LEADER |
00000cam a2200000 i 4500 |
001 |
EBOOKCENTRAL_ocn985701994 |
003 |
OCoLC |
005 |
20240329122006.0 |
006 |
m o d |
007 |
cr cnu---unuuu |
008 |
170505s2017 nju ob 001 0 eng d |
040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d OCLCO
|d YDX
|d EBLCP
|d N$T
|d OCLCO
|d OCLCF
|d OCLCO
|d AU@
|d OCLCO
|d U3W
|d OCLCA
|d OCLCQ
|d OCLCO
|d OCLCA
|d OCLCO
|d OCLCQ
|d OCLCO
|d K6U
|d OCLCQ
|d OCLCO
|d OCLCL
|
020 |
|
|
|a 9781630913229
|q (electronic bk.)
|
020 |
|
|
|a 1630913227
|q (electronic bk.)
|
020 |
|
|
|a 1630913235
|
020 |
|
|
|a 9781630913236
|
020 |
|
|
|z 9781630913212
|
020 |
|
|
|z 1630913219
|
020 |
|
|
|z 9781630913236
|q (Web)
|
029 |
1 |
|
|a AU@
|b 000071983773
|
035 |
|
|
|a (OCoLC)985701994
|
050 |
|
4 |
|a RE991
|
060 |
|
4 |
|a WW 166
|
072 |
|
7 |
|a MED
|x 085000
|2 bisacsh
|
082 |
0 |
4 |
|a 617.7/061
|2 23
|
049 |
|
|
|a UAMI
|
245 |
0 |
0 |
|a Anti-VEGF use in ophthalmology /
|c editors, Jay S. Duker, Michelle C. Liang.
|
246 |
3 |
|
|a Anti-vascular endothelial growth factor use in ophthalmology
|
264 |
|
1 |
|a Thorofare, NJ :
|b SLACK Incorporated,
|c [2017]
|
300 |
|
|
|a 1 online resource
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
504 |
|
|
|a Includes bibliographical references and index.
|
505 |
0 |
|
|a Vascular endothelial growth factor : background and history / Anthony Joseph and Ehsan Rahimy -- Development of anti-vascular endothelial growth factor agents / Maya H. Maloney and Sophie J. Bakri -- Available anti-vascular endothelial growth factor agents / Angeline Mariani-Derham and David M. Brown -- Agents under study / Anthony Joseph, Elham Rahimy, and Ehsan Rahimy -- Intravitreal delivery / Nora Muakkassa, Kendra Klein, and Elias Reichel -- Sustained anti-vascular endothelial growth factor delivery options / Michael N. Cohen, Chirag P. Shah, and Jeffrey S. Heier -- Neovascular age-related macular degeneration / Michael D. Lewen and Andre J. Witkin -- Choroidal neovascularization, not age-related macular degeneration / Darin R. Goldman -- Diabetic macular edema / Emily D. Cole, Eduardo A. Novais, and Nadia K. Waheed -- Proliferative diabetic retinopathy / Sabin Dang and Chirag P. Shah -- Retinal vein occlusion / Shilpa Desai and Caroline R. Baumal -- Uveitis / Lana M. Rifkin -- Retinopathy of prematurity / Nikisha A. Kothari and Audina M. Berrocal -- Miscellaneous retinal and choroidal diseases / Michael D. Tibbetts -- Neovascular glaucoma / Manik Goel and Joel S. Schuman -- Glaucoma surgery / Jessica J. Moon and Cynthia Mattox -- Anterior segment diseases / Alessandro Abbouda, Bijan Khaksari, and Pedram Hamrah.
|
520 |
|
|
|a "The introduction of anti-vascular endothelial growth factor (VEGF) agents has revolutionized therapy for a host of ocular diseases associated with leakage from normal blood vessels and pathologic blood vessel growth. Anti-VEGF Use in Ophthalmology is an all-inclusive reference designed to provide detailed, up-to-date, and clinically relevant information on the current use of anti-VEGF agents in the treatment of all ocular conditions. Drs. Jay S. Duker and Michelle C. Liang have assembled a prestigious group of contributors who pool their collective expertise in this comprehensive book. Anti-VEGF Use in Ophthalmology is split into two sections with the first providing the history of VEGF and an overview of anti-VEGF agents and different routes of drug delivery, as it is important for eye care providers to be familiar with up-to-date aspects of the medications and indications for use. The second section details the clinical uses of anti-VEGF agents in numerous ocular diseases, from the anterior segment including cornea and glaucoma to uveitis and various retinal and choroidal diseases. Each chapter in this section summarizes the disease process and utilizes high-quality ocular imaging to demonstrate the therapeutic use of the anti-VEGF agents. Anti-VEGF Use in Ophthalmology combines the theory and applications of anti-VEGF agents, making it not only a great learning tool for beginners but also a useful reference tool for a wide range of eye care professionals including optometrists, residents, comprehensive ophthalmologists, as well as specialists in anterior segment, pediatrics, and vitreoretinal disease"--Provided by publisher
|
588 |
0 |
|
|a Print version record.
|
590 |
|
|
|a ProQuest Ebook Central
|b Ebook Central Academic Complete
|
650 |
|
0 |
|a Therapeutics, Ophthalmological.
|
650 |
|
0 |
|a Vascular endothelial growth factors
|x Antagonists.
|
650 |
|
0 |
|a Vascular endothelial growth factors
|x Therapeutic use.
|
650 |
1 |
2 |
|a Eye Diseases
|x drug therapy
|
650 |
2 |
2 |
|a Vascular Endothelial Growth Factor A
|x antagonists & inhibitors
|
650 |
2 |
2 |
|a Angiogenesis Inhibitors
|x therapeutic use
|
650 |
2 |
2 |
|a Neovascularization, Pathologic
|x drug therapy
|
650 |
|
6 |
|a Œil
|x Maladies
|x Traitement.
|
650 |
|
7 |
|a MEDICAL
|x Surgery
|x General.
|2 bisacsh
|
650 |
|
7 |
|a Therapeutics, Ophthalmological
|2 fast
|
650 |
|
7 |
|a Vascular endothelial growth factors
|x Antagonists
|2 fast
|
700 |
1 |
|
|a Duker, Jay S.,
|d 1958-
|e editor.
|1 https://id.oclc.org/worldcat/entity/E39PCjJ84464HTvxBw49gVV7pd
|
700 |
1 |
|
|a Liang, Michelle C.,
|d 1983-
|e editor.
|1 https://id.oclc.org/worldcat/entity/E39PCjwghb9db9wV9KkjGjbq33
|
758 |
|
|
|i has work:
|a AntiGF use in ophthalmology (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCGby99fBMBkxGmjx4pXXBd
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
776 |
0 |
8 |
|i Print version:
|t Anti-VEGF use in ophthalmology
|z 9781630913212
|w (DLC) 2017010954
|w (OCoLC)966392686
|
856 |
4 |
0 |
|u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=4854426
|z Texto completo
|
938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL4854426
|
938 |
|
|
|a EBSCOhost
|b EBSC
|n 1514353
|
938 |
|
|
|a YBP Library Services
|b YANK
|n 14358548
|
938 |
|
|
|a YBP Library Services
|b YANK
|n 14293551
|
994 |
|
|
|a 92
|b IZTAP
|